{
  "abstract": "Bruton tyrosine kinase inhibitors (BTKi) are a pivotal advancement in treating chronic lymphocytic leukemia (CLL). However, their adoption faces challenges such as high discontinuation rates caused by adverse events like cardiac and hematologic toxicities and a significant financial burden. Our study aims to evaluate the clinical spectrum and outcomes of patients with CLL receiving BTKi therapy in India. The objectives are to evaluate progression-free survival and overall survival in CLL patients on BTKi and to assess the BTKi toxicity profile. This retrospective, single-center study analyzed data from 41 patients with CLL treated with BTKi between January 2019 and November 2024. Twenty-five male patients and 16 female patients were evaluated, with a median age of 64 years (range 42-90). Twelve patients (29.2%) had no cytogenetic abnormalities, while 29 (70.7%) had at least one abnormality; 13q deletion was the most common. BTKi was used as first-line therapy in 29 patients (70.7%), with acalabrutinib being the most commonly used agent, administered to 17 (58.6%) patients. Cardiac events were observed in 8 (19.5%) patients, including hypertension in four (9.7%) and atrial fibrillation in two (4.9%). Gastrointestinal adverse events were noted in 7 (17%) patients. One patient had Richter transformation to diffuse large B-cell lymphoma. At a median follow-up of 24 months, progression-free survival was 80% and overall survival was 95%. BTKi therapy is effective and well tolerated in Indian CLL patients, but early discontinuation highlights the need for improved adherence strategies.",
  "abstract_shown": true,
  "affiliations": [
    "Hematology and Oncology/Clinical Hematology, King George's Medical University, Lucknow, IND.",
    "Medical Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, IND.",
    "Clinical Hematology, King George's Medical University, Lucknow, IND.",
    "Hematology and Oncology/Clinical Hematology, Hind Institute of Medical Sciences, Lucknow, IND.",
    "Statistics, University of Lucknow, Lucknow, IND."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Alpika Shukla"
    },
    {
      "affs": [
        1
      ],
      "name": "Amit Pandey"
    },
    {
      "affs": [
        0
      ],
      "name": "Shailendra P Verma"
    },
    {
      "affs": [
        2
      ],
      "name": "Swasti Sinha"
    },
    {
      "affs": [
        3
      ],
      "name": "Anil Tripathi"
    },
    {
      "affs": [
        4
      ],
      "name": "Neha Shukla"
    },
    {
      "affs": [
        0
      ],
      "name": "Gaurav Dutta"
    },
    {
      "affs": [
        0
      ],
      "name": "P Raghuveer"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6tmym1ck8ff7c.bib",
  "cited_by": 0,
  "doi": "10.7759/cureus.117629",
  "fulltext_url": "https://europepmc.org/articles/PMC13744091",
  "id": "6tmym1ck8ff7c",
  "issns": [
    "2168-8184"
  ],
  "landing_url": "https://europepmc.org/article/MED/42999795",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2720|Chronic Lymphocytic Leukemia Research"
    ]
  ],
  "openalex": "W7220983098",
  "pdf_url": "https://europepmc.org/articles/PMC13744091?pdf=render",
  "pmcid": "PMC13744091",
  "pmid": "42999795",
  "published": "2026-10-08",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/6tmym1ck8ff7c.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T15:20:41Z",
      "native_id": "MED:42999795",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42999795"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2720|Chronic Lymphocytic Leukemia Research",
      "subfield": "general"
    }
  ],
  "title": "Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors (BTKi): A Retrospective Study From a Tertiary Healthcare Center in North India.",
  "title_text": "Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors (BTKi): A Retrospective Study From a Tertiary Healthcare Center in North India.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T15:20:41Z",
  "url": "https://research.draconitic.com/paper/6tmym1ck8ff7c",
  "venue": "Cureus",
  "versions": []
}